Amgen, Inc. vs iShares MSCI Hong Kong ETF — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while iShares MSCI Hong Kong ETF trades at $22.46. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares MSCI Hong Kong ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | EWH | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $417.20 | $24.55 |
52-Week Low | $271.18 | $20.66 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
EWH, a US-listed ETF tracking Hong Kong equities, trades at $22.45, down 1.54% in the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF announced a $0.35 dividend payable in June 2026. Recent news highlights the Hang Seng Index's rebound, driven by technology stock recoveries, contrasting with declines in other Asian markets like the Kospi and Nikkei 225.
The outlook for EWH is mixed, with potential upside from Hong Kong's market recovery and tech sector momentum, but risks include regional volatility and competitive pressures. Investors should weigh the ETF's exposure to Asian economic shifts and monitor earnings growth from constituent companies for catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →